Erastin: A Precision Ferroptosis Inducer for Cancer Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, a form of iron-dependent, non-apoptotic cell death, by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating the voltage-dependent anion channel (VDAC) (Yang et al., 2021). It exhibits selectivity against tumor cells with oncogenic RAS or BRAF mutations (APExBIO product information). Erastin is widely used in oxidative stress assays, cancer biology research, and mechanistic ferroptosis studies. The compound is a standard for modeling and benchmarking ferroptotic cell death in vitro, especially in engineered tumor cell lines. Proper solubilization and storage are critical for reproducible results in experimental workflows.

Biological Rationale

Ferroptosis is a distinct, iron-dependent cell death pathway characterized by the accumulation of lipid peroxides and depletion of intracellular antioxidants such as glutathione. Unlike apoptosis or necrosis, ferroptosis involves lethal oxidative damage orchestrated by imbalances in cellular redox systems (Yang et al., 2021). Tumor cells with RAS or BRAF mutations display heightened sensitivity to perturbations in redox homeostasis, making them particularly vulnerable to ferroptosis inducers like Erastin. Targeting ferroptosis is of growing interest in cancer biology research because it offers a strategy to eliminate apoptosis-resistant tumors and reveals novel vulnerabilities (see additional mechanistic insights).

Mechanism of Action of Erastin

Erastin acts through two primary mechanisms. First, it directly inhibits the cystine/glutamate antiporter system Xc⁻ (SLC7A11), blocking cystine import and reducing glutathione synthesis. Second, Erastin modulates VDAC on the mitochondrial outer membrane, altering mitochondrial metabolism and further increasing oxidative stress (APExBIO). The combination of cystine deprivation and VDAC modulation leads to rapid accumulation of reactive oxygen species (ROS) and lipid peroxides, key hallmarks of ferroptosis. This distinct mechanism differentiates Erastin from classical apoptosis inducers, as ferroptotic cell death is caspase-independent (see advanced insights into caspase-independent death).

Evidence & Benchmarks

• ALOXE3 downregulation in glioblastoma cells confers resistance to p53-SLC7A11-dependent ferroptosis, underscoring the pathway's therapeutic relevance (Yang et al., 2021).
• Erastin selectively induces ferroptotic cell death in RAS- or BRAF-mutant tumor cell lines at concentrations around 10 μM for 24 hours, as established in multiple in vitro models (APExBIO).
• Ferroptosis induced by Erastin is iron- and lipotoxicity-dependent, and is not prevented by caspase inhibitors (Yang et al., 2021).
• Erastin’s inhibition of system Xc⁻ leads to depletion of intracellular cystine and glutathione, resulting in elevated ROS and lipid peroxidation (APExBIO).
• Validated oxidative stress assays confirm that Erastin treatment produces reproducible increases in ROS in engineered tumor cells (see protocols and research impact).

Applications, Limits & Misconceptions

Erastin is used extensively as a ferroptosis inducer in cancer biology research, particularly for studying redox vulnerabilities in RAS/RAF-mutant tumor cells. It is also employed in oxidative stress assays and for dissecting the interplay between lipid metabolism and cell death. However, its activity is limited to cells expressing functional system Xc⁻ and is less effective in non-tumor or system Xc⁻-deficient cells. Its solubility profile (insoluble in water and ethanol; soluble in DMSO) and instability in solution necessitate careful handling and fresh preparation (see APExBIO usage recommendations). For additional context on Erastin’s role in biomarker discovery and translational oncology, see the extended discussion in this article, which further explores its caspase-independent mechanism and research impact.

Common Pitfalls or Misconceptions

• Erastin does not induce classical apoptosis; cell death is caspase-independent and will not be prevented by pan-caspase inhibitors.
• Its efficacy is restricted to cells with active system Xc⁻; in SLC7A11-deficient models, ferroptosis induction is minimal.
• Erastin is unstable in aqueous solution; pre-prepared solutions should not be stored at room temperature for extended periods.
• Not suitable for in vivo studies without rigorous pharmacokinetic optimization, as most published work supports in vitro use.
• Erastin's selectivity for RAS/BRAF mutations does not guarantee activity in all tumor subtypes; genetic background must be confirmed.

Workflow Integration & Parameters

Erastin (APExBIO B1524) can be integrated into standard oxidative stress and ferroptosis research workflows. The following protocol parameters are recommended, with distinctions between literature-backed values and practical usage guidance:

Protocol Parameters

• Compound preparation: Dissolve Erastin in DMSO at ≥10.92 mg/mL with gentle warming; avoid water and ethanol due to insolubility (APExBIO).
• Working solution: Prepare fresh immediately before use; typical concentration for in vitro assays is 10 μM.
• Cell treatment: Apply to engineered tumor cells or HT-1080 fibrosarcoma cells for 24 hours to induce ferroptosis.
• Storage: Store solid at -20°C; DMSO stock solutions stable for several months at -20°C (APExBIO).
• Controls: Include iron chelators and antioxidants to confirm ferroptosis specificity.

For a stepwise integration and troubleshooting guide, see the complementary resource "Erastin: Ferroptosis Inducer Workflows for Cancer Biology Research", which details protocol enhancements and best practices.

Conclusion & Outlook

Erastin is a rigorously validated ferroptosis inducer essential for studying oxidative cell death pathways in RAS- and BRAF-driven tumor models. Its unique mechanism—system Xc⁻ inhibition and VDAC modulation—makes it pivotal for dissecting redox vulnerabilities in cancer cells (Yang et al., 2021). Ongoing research continues to refine its use in biomarker discovery and functional genomics of ferroptosis. For comprehensive product specifications and ordering, visit the official APExBIO Erastin page.